Slide 1: Oriola Corporation Half year financial report January-June 2021
Oriola Corporation Half year financial report January-June 2021
Slide 2: Q2 2021 key points
Q2 2021 key points ” Markets recovering, Oriola progressing in many areas" • Oriola’s business started to recover both in Finland and in Sweden. • Invoicing up by 5.9% and net sales by 3.3% in constant currency from the very low comparison period. • Adjusted EBIT increased to EUR 4.1 (-0.3) million,
Slide 3: Key figures
Key figures continuing operations Invoicing Net sales Adjusted EBIT EUR million EUR million EUR million 4 000 3 765 2 000 50 3 733 3 518 1 801 3 500 3 336 1 721 1 528 1 552 40 39.0 3 000 1 500 34.4 2 500 30 2 000 1 000 20.5 21.0 20 1 500 984 897 942 898 436 468 12.8 844 399 448 1 000 500 387 10 6.6
Slide 4: Adjusted EBIT
Adjusted EBIT Adjusted EBIT Adjusted EBIT development1 EUR million EUR million 10 10 8 8 6 6 9.1 0.2 4 8.0 4 6.9 6.3 2.3 2 4.1 2 0.1 4.1 2.1 -0.3 0.3 -0.3 1.7 0 0 2020 Consumer Pharma Retail Group 2021 2019 2019 2020 2020 2020 2020 2021 2021 Q2 items Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Oriola estimates that
Slide 5: Operating environment
& Oriola Operating environment
Slide 6: Consumer markets
Consumer markets Pharmacy market value and volume grew in Sweden in Q2 Pharmacy market value development in Sweden in Q2: +7.0% Online pharmacy market size in Sweden Market shares Pharmacy 397 market BSEK 3 2 1 0 49 BSEK 49 BSEK 2019 Q2 2021 Q2 2017 Q1 2017 Q2 2017 Q3 2017 Q4 2018 Q1 2018 Q2 2018 Q3
Slide 7: Pharma markets
Pharma markets Pharmaceutical market value and volume grew in Q2 Pharmaceutical market value development in Q2: Finland +8.4% and Sweden +7.2% Finland Wholesale Sweden Wholesale 2.8 BEUR 49 BSEK Oriola 43% (43%) Oriola 46% (47%) Others 57% (57%) Others 54% (53%) Market shares are quarterly Source: L
Slide 8: Retail markets
Retail markets Market share dose dispensing TG/OTC products supply for pharmacies in Sweden Sweden Oriola 43% (43%) Total 235,000 Others 57% (57%) 25% (25%) patients from the total market of SEK 13 billion Market share is quarterly figure and market size rolling 12 month figure. Source: Apoteksfören
Slide 9: Business Area reviews Q2 2021
Business Area reviews Q2 2021
Slide 10: Three customer-centric business areas
Three customer-centric business areas Consumer business area Pharma business area Retail business area Pharmacy services and products for Advanced logistics, expert and advisory A wide range of health and wellbeing consumer health and wellbeing in Sweden services for pharmaceutical companies, produc
Slide 11: Consumer Q2: Pharmacy market started to pick up, profitability improved
Consumer Q2: Pharmacy market started to pick up, profitability improved • Consumer activity and demand started to recover Adjusted EBIT towards the end of the quarter EUR million • COVID-19 restrictions continued to impact high consumer density pharmacies located e.g. in shopping centres 6 • Net sal
Slide 12: Pharma Q2: Flat profit, volumes picking up and market recovering
Pharma Q2: Flat profit, volumes picking up and market recovering • Market demand recovering in both countries Adjusted EBIT EUR million • Continued volatility in volumes • Invoicing increased by 5.8% to EUR 729.9 million in 6 constant currency 5 • Net sales stayed flat at EUR 234.9 million in consta
Slide 13: Retail Q2: Continued strength in dose dispensing business
Retail Q2: Continued strength in dose dispensing business, improvement in other areas as well • Demand increased in dose dispensing and Adjusted EBIT EUR million parallel import. • Net sales increased by 3.1% to EUR 124.7 2.0 million in constant currency, driven by 1.5 • Growth of patient volumes in
Slide 14: Financial review Q2 2021
& Oriola Financial review Q2 2021
Slide 15: Invoicing and net sales
Invoicing and net sales Invoicing1 Net sales2 EUR million EUR million 1 000 500 800 400 600 300 979 965 987 942 984 460 466 468 917 898 915 429 447 436 439 450 400 200 979 200 100 0 0 2019 2019 2020 2020 2020 2020 2021 2021 2019 2019 2020 2020 2020 2020 2021 2021 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Slide 16: Adjusted EBIT
Adjusted EBIT Adjusted EBIT Adjusted EBIT development1 EUR million EUR million 10 10 8 8 6 6 9.1 0.2 4 8.0 4 6.9 6.3 2.3 2 4.1 2 0.1 4.1 2.1 -0.3 0.3 -0.3 1.7 0 0 2020 Consumer Pharma Retail Group 2021 2019 2019 2020 2020 2020 2020 2021 2021 Q2 items Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Oriola estimates that
Slide 17: Profit for the period and earnings per share
Profit for the period and earnings per share Profit for the period Earnings per share EUR million EUR 6 0.06 4 0.04 0.03 5.1 0.02 0.02 2 3.7 4.1 0.02 0.01 2.0 0.01 0.9 0 0.00 -0.2 0.00 -1.6 -1.7 -0.01 -0.01 -2 -0.02 2019 2019 2020 2020 2020 2020 2021 2021 2019 2019 2020 2020 2020 2020 2021 2021 Q3 Q
Slide 18: Cash flow
Cash flow Quarterly net cash flow from operating activities H1 2021 change in cash EUR million EUR million 80 250 60 18.0 200 14.0 40 -48.6 150 20 46 27 28 13 0 100 0 9 4 168.2 -14 151.6 50 -20 -40 0 2019 2019 2020 2020 2020 2020 2021 2021 Cash Operating Investing Financing Cash Q3 Q4 Q1 Q2 Q3 Q4 Q1
Slide 19: Net Interest-Bearing Debt
Net Interest-Bearing Debt Net interest-bearing debt Net interest-bearing debt items EUR million EUR million 200 Net interest-bearing debt item 31 Jun 2021 31 Jun 2020 Bank loans 86.7 127.7 (syndicated Bank & term) 150 Commercial papers 71.5 96.7 Advance payment from pharmacies 21.9 18.7 100 Lease li
Slide 20: Q2 2021 Key take-aways
Q2 2021 Key take-aways ”Markets recovering, Oriola progressing in many areas” Markets Profitability A quarter packed New Delivering our recovering, the improved, driven with action, President and purpose pandemic impact by volumes and several CEO starting “Health for life” visible mainly in strong d
Slide 21: Outlook for 2021 unchanged
Outlook for 2021 unchanged The adjusted EBIT on a constant currency basis stays on the same level or increases from the 2020 level. The COVID-19 pandemic is expected to continue during 2021. Severity and duration of the pandemic remain unclear in Oriola’s operating environment. Oriola’s business out
Slide 22: Thank you!
Thank you! Our next events: 27/10/2021 Interim Report 1-9/2021 25/11/2021 Capital Markets Day IR contact: Katja Graff, Treasury & IR Manager, +358 10 429 013 or katja.graff@oriola.com